Tuesday, October 19, 2021  | 12 Rabiulawal, 1443
Samaa TV
Facebook Twitter Youtube
HOME > Health

Chinese COVID-19 vaccines show safety, but data lacking: WHO

Sinopharm, Sinovac efficacy unknown in older people, those with comorbidities

SAMAA | - Posted: Mar 31, 2021 | Last Updated: 7 months ago
SAMAA |
Posted: Mar 31, 2021 | Last Updated: 7 months ago

A staff member checks vaccines during a media tour of a new factory built to produce a COVID-19 coronavirus vaccine at Sinovac, one of 11 Chinese companies approved to carry out clinical trials of potential coronavirus vaccines, in Beijing on September 24, 2020. Photo: AFP

Listen to the story
WHO vaccine experts said Wednesday that an interim analysis of clinical trial data from two Chinese Covid-19 vaccines showed they demonstrated "safety and good efficacy", but that more data was needed. The Chinese firms Sinovac and Sinopharm, whose Covid jabs are already being used in several countries, have submitted data in applications for the World Health Organization's emergency use listing (EUL) green light. The UN health agency's Strategic Advisory Group of Experts on Immunization (SAGE) said it had reviewed the data provided so far, and that both vaccines "demonstrated safety and good efficacy against symptomatic Covid-19 disease". However, it warned, "both vaccines lacked data in older age groups and in persons with co-morbidities," meaning other medical conditions. "Post-introduction vaccine effectiveness and safety studies will be needed to address the impact on those sub-populations," SAGE said in a list of highlights published after a meeting last week to discuss developments on vaccines against a range of diseases. The two vaccines are among four homegrown jabs that have been approved by Chinese regulators so far, but SAGE pointed out that neither had yet received authorisation by what the WHO considers "a stringent regulatory authority". SAGE, which advises the WHO on immunisation policies, said it would hold off on issuing recommendations for how the two Chinese vaccines should best be used until after another expert panel rules on their EUL applications. An emergency use listing by the WHO paves the way for countries worldwide to quickly approve and import a vaccine for distribution.  It also opens the door for the jabs to enter the Covax global vaccine-sharing scheme, which aims to provide equitable access to doses around the world and particularly in poorer countries. "For now, we have information that these vaccines are safe, and that they are in the process of defining their final analysis to show the efficacy that will be used for the emergency use listing approval," SAGE chair Alejandro Cravioto told reporters.  "Once that is in place we will be able to make the necessary recommendations for its use." The WHO has so far granted emergency use listing to the Covid vaccines made by Pfizer/BioNTech, AstraZeneca/Oxford and Johnson & Johnson.
FaceBook WhatsApp

WHO vaccine experts said Wednesday that an interim analysis of clinical trial data from two Chinese Covid-19 vaccines showed they demonstrated “safety and good efficacy”, but that more data was needed.

The Chinese firms Sinovac and Sinopharm, whose Covid jabs are already being used in several countries, have submitted data in applications for the World Health Organization’s emergency use listing (EUL) green light.

The UN health agency’s Strategic Advisory Group of Experts on Immunization (SAGE) said it had reviewed the data provided so far, and that both vaccines “demonstrated safety and good efficacy against symptomatic Covid-19 disease”.

However, it warned, “both vaccines lacked data in older age groups and in persons with co-morbidities,” meaning other medical conditions.

“Post-introduction vaccine effectiveness and safety studies will be needed to address the impact on those sub-populations,” SAGE said in a list of highlights published after a meeting last week to discuss developments on vaccines against a range of diseases.

The two vaccines are among four homegrown jabs that have been approved by Chinese regulators so far, but SAGE pointed out that neither had yet received authorisation by what the WHO considers “a stringent regulatory authority”.

SAGE, which advises the WHO on immunisation policies, said it would hold off on issuing recommendations for how the two Chinese vaccines should best be used until after another expert panel rules on their EUL applications.

An emergency use listing by the WHO paves the way for countries worldwide to quickly approve and import a vaccine for distribution. 

It also opens the door for the jabs to enter the Covax global vaccine-sharing scheme, which aims to provide equitable access to doses around the world and particularly in poorer countries.

“For now, we have information that these vaccines are safe, and that they are in the process of defining their final analysis to show the efficacy that will be used for the emergency use listing approval,” SAGE chair Alejandro Cravioto told reporters. 

“Once that is in place we will be able to make the necessary recommendations for its use.”

The WHO has so far granted emergency use listing to the Covid vaccines made by Pfizer/BioNTech, AstraZeneca/Oxford and Johnson & Johnson.

 
HOME  
 
 
RELATED STORIES

Tell us what you think:

Your email address will not be published.

FaceBook WhatsApp
 
 
 
World health organisation, WHO, China vaccines, Sinopharm vaccine, CanSinoBio vaccines, Sinovac vaccines, china vaccines safety
 

MOST READ
MOST READ
Imtiaz Super Market robbed of nearly a million: police
Here’s Karachi’s traffic plan for 12th Rabiul Awwal
DG ISI Gen Faiz Hameed briefs COAS on security: ISPR
Policeman martyred in explosion outside Quetta university
Govt moves to cut taxes on commodities for price reduction
IMF talks, PPP, PDM announce protests, petrol price hikes
Malala writes to Taliban one month after girls’ school ban
Inflation to go down from March next year: Asad Umar
 
 
 
 
 
About Us   |   Anchor Profiles   |   Online Advertising   |   Contact Us   |   Feedback   |   Apps   |   FAQs   |   Authors   |   Comment Policy
Facebook   |   Twitter   |   Instagram   |   YouTube   |   WhatsApp